Barclays Maintains an 'Overweight' on Halozyme Therapeutics (HALO); Underappreciated Assets Plus Possible Partnership On Deck
Tweet Send to a Friend
Barclays maintains an 'Overweight' on Halozyme Therapeutics (NASDAQ: HALO) price target of $15.00.
Analyst, Ying Huang, attended the American ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Analyst, Ying Huang, attended the American ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
